Get the Stockscreener App
20.68
0.31%
0.32
Gh Research Plc stock is traded at $20.68, with a volume of 125.47K.
It is up +0.31% in the last 24 hours and down -3.94% over the past month.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
See More
Previous Close:
$20.36
Open:
$20.54
24h Volume:
125.47K
Relative Volume:
0.54
Market Cap:
$1.42B
Revenue:
-
Net Income/Loss:
$-48.26M
P/E Ratio:
-26.18
EPS:
-0.7899
Net Cash Flow:
$-45.04M
1W Performance:
-12.16%
1M Performance:
-3.94%
6M Performance:
+47.99%
1Y Performance:
+48.10%
1-Day Range:
$20.00
$20.95
1-Week Range:
$19.74
$23.61
52-Week Range:
$11.32
$25.94
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
20.66 | 1.40B | 0 | -48.26M | -45.04M | -0.7899 |
VRTX
Vertex Pharmaceuticals Inc
|
443.25 | 110.59B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
616.64 | 63.08B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
895.18 | 53.62B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
292.97 | 38.88B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.49 | 30.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Needham | Buy |
| Jun-04-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Mar-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Feb-13-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-16-22 | Initiated | H.C. Wainwright | Buy |
| Jun-16-22 | Initiated | ROTH Capital | Buy |
View All
Gh Research Plc Stock (GHRS) Latest News
Do GH Research’s (GHRS) Phase 2a Postpartum Data Subtly Reframe Its Broader Depression Strategy? - simplywall.st
GH Research Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues Clinical DevelopmentReturn On Assets - newsline.com
GHRS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
H.C. Wainwright Maintains Buy Rating on GH Research (GHRS) - Insider Monkey
GH RESEARCH PLC (GHRS) Stock Chart - ChartMill
GH Research earnings ahead: Can cash sustain Phase 3 ambitions? - Investing.com
5 Stocks That Have the Potential to Rise 1000% - Insider Monkey
(GHRS) Risk Channels and Responsive Allocation - Stock Traders Daily
GH Research Publishes Positive Phase 2a Postpartum Depression Data and Secures CINP 2026 Slots for GH001 - TipRanks
GH Research (NASDAQ: GHRS) highlights Phase 2 GH001 results in postpartum and treatment-resistant depression - Stock Titan
GH Research publishes phase 2a postpartum depression results By Investing.com - Investing.com Australia
GH Research publishes phase 2a postpartum depression results - Investing.com
GH Research Announces Publication of Phase 2a Postpartum Depression Results - Yahoo Finance UK
GH Research (GHRS) 10K Form and Latest SEC Filings 2026 - MarketBeat
GHRS Technical Analysis | Trend, Signals & Chart Patterns | GH RESEARCH PLC (NASDAQ:GHRS) - ChartMill
Psychedelic drug stocks are surging after Trump's order to fast-track development for medical use - AOL.com
GH Research (GHRS) Surges 7.19% as Breakout Above $25.19 Resistance Becomes Key TestOvernight Profile - The Legal Advocate
Certain Options of GH Research PLC are subject to a Lock-Up Agreement Ending on 30-MAY-2026. - marketscreener.com
62,029,395 Common Stock of GH Research PLC are subject to a Lock-Up Agreement Ending on 30-MAY-2026. - marketscreener.com
GH Research (GHRS) Jumps 3.35% as Shares Approach Key Resistance at $24.0Insider Selling Alerts - The Legal Advocate
(GHRS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
GH Research Stock Moves as Market Eyes Data in Holiday Week - Bez Kabli
Assessing GH Research (GHRS) Valuation After Positive Phase 2b Data For GH001 In Treatment Resistant Depression - Sahm
GH Research to Present New GH001 Phase 2b Data in Treatment-Resistant Depression at ASCP 2026 - TipRanks
GH Research (NASDAQ: GHRS) highlights Phase 2b GH001 gains in treatment-resistant depression - Stock Titan
[EFFECT] GH Research PLC SEC Filing - Stock Titan
GH Research: Rapid Onset And Short Action Change The Treatment Paradigm (NASDAQ:GHRS) - Seeking Alpha
GHRS Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
H.C. Wainwright lowers GH Research stock price target on dilution By Investing.com - Investing.com South Africa
H.C. Wainwright lowers GH Research stock price target on dilution - Investing.com
Lynx1 and Weston Nichols report 17.4% stake in GH Research (NASDAQ: GHRS) - Stock Titan
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Phase 2b JAMA Data and New Financing Tools Could Be A Game Changer For GH Research (GHRS) - simplywall.st
Assessing GH Research (GHRS) Valuation After Key Phase 2b Results And Phase 3 Trial Plans - Yahoo Finance
GHRS SEC FilingsGh Research Plc 10-K, 10-Q, 8-K Forms - Stock Titan
GHRS Maintained by Cantor Fitzgerald -- Price Target Raised to $35 - GuruFocus
Lynx1 discloses 15.2% stake in GHRS (GHRS) via Schedule 13G/A - Stock Titan
GHRS Maintained by CitizensPrice Target Lowered to $39.00 - GuruFocus
Cantor Fitzgerald raises GH Research stock price target on adoption outlook - Investing.com UK
These Analysts Revise Their Forecasts On GH Research After Q1 Results - Benzinga
Canaccord reiterates GH Research stock rating on phase 3 progress By Investing.com - Investing.com Nigeria
Cantor Fitzgerald raises GH Research stock price target on adoption outlook By Investing.com - Investing.com South Africa
Canaccord reiterates GH Research stock rating on phase 3 progress - Investing.com
Citizens cuts GH Research stock price target on equity financing - Investing.com
Citizens cuts GH Research stock price target on equity financing By Investing.com - Investing.com Australia
Gh Research Plc Stock (GHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.02%
2.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):